Clinical Pediatric Emergency Medicine
Volume 9, Issue 1 , Pages 4-16 , March 2008

Management of Beta-Adrenergic Blocker Poisoning

  • Angela C. Anderson, MD, FAAP

      Affiliations

    • Corresponding Author InformationReprint requests and correspondence: Angela C. Anderson, MD, FAAP, Pediatric Emergency Medicine, Hasbro Children's Hospital, Providence, RI.

References 

  1. Lai MW, Klein-Schwartz W, Rodgers GC, et al. 2005 Annual report of the American Association of Poison Control Centers' national poisoning and exposure database. Clin Toxicol. 2006;44:803–932
  2. Kendall MJ, Dean S, Bradley D, et al. Cardiovascular and metabolic effects of terbutaline. J Clin Hosp Pharm. 1982;7:31–36
  3. Kendall MJ, Lewis HM, Haffner CA, et al. Investigation of the beta 2-agonist properties of dilevalol: metabolic effects of intravenous infusion. J Hum Hypertens. 1990;4(Suppl 2):65–68
  4. Kendall MJ, Hafner CA, Hughes B, et al. The adrenergic control of lipolysis: development of tolerance to beta-2 receptor stimulation with terbutaline. Clin Chim Acta. 1991;204:51–55
  5. Tavernier G, Toumaniantz G, Erfanian M, et al. beta3-Adrenergic stimulation produces a decrease of cardiac contractility ex vivo in mice overexpressing the human beta3-adrenergic receptor. Cardiovasc Res. 2003;59:288–296
  6. Osawa S, Heasley LE, Dhanasekaran N, et al. Mutation of the Gs protein alpha subunit NH2 terminus relieves an attenuator function, resulting in constitutive adenylyl cyclase stimulation. Mol Cell Biol. 1990;10:2931–2940
  7. Kaumann AJ. Four beta-adrenoceptor subtypes in the mammalian heart. Trends Pharmacol Sci. 1997;18:70–76
  8. Kendall MJ. Do we need a new classification of beta-blockers?. J Hum Hypertens. 1990;4(Suppl 2):27–29
  9. Salpeter SR, Ormiston TM, Salpeter EE, et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med. 2003;97:1094–1101
  10. Pedersen ME, Cockcroft JR. The latest generation of beta-blockers: new pharmacologic properties. Curr Hypertens Rep. 2006;8:279–286
  11. Brody G. Type II antidysrhythmic agents (beta-receptor blocking agents). In:  Dart R editors. Medical toxicology. Philadelphia: Lippincott Williams & Wilkins; 2004;p. 679–689
  12. Hollander JE. The management of cocaine-associated myocardial ischemia. N Engl J Med. 1995;333:1267–1272
  13. Boehrer JD, Moliterno DJ, Willard JE, et al. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans. Am J Med. 1993;94:608–610
  14. Jasper JR, Michel MC, Insel PA. Molecular mechanism of beta-adrenergic receptor blockers with intrinsic sympathomimetic activity. FASEB J. 1988;2:2891–2894
  15. Kostis JB, Rosen RC. Central nervous system effects of beta-adrenergic-blocking drugs: the role of ancillary properties. Circulation. 1987;75:204–212
  16. Black CD, Mann HJ. Intrinsic sympathomimetic activity: physiological reality or marketing phenomenon. Drug Intell Clin Pharm. 1984;18:554–559
  17. Kaumann AJ, Molenaar P. Modulation of human cardiac function through 4 beta-adrenoceptor populations. Naunyn Schmiedebergs Arch Pharmacol. 1997;355:667–681
  18. Joseph SS, Lynham JA, Molenaar P, et al. Intrinsic sympathomimetic activity of (−)-pindolol mediated through a (−)-propranolol–resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003;368:496–503
  19. Love JN. Acebutolol overdose resulting in fatalities. J Emerg Med. 2000;18:341–344
  20. Ramos K, Melchert R, Chacon E, Acosta D. Toxic responses of the heart and vascular systems. In:  Casarett LJ,  Doull J,  Klaassen CD editor. The basic science of poisons. 6th ed.. New York: McGraw-Hill Medical Pub. Division; 2001;p. 597–651
  21. DeWitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. Toxicol Rev. 2004;23:223–238
  22. Brubacher J. Beta adrenergenic antagonists. In:  Goldfrank LR editors. Goldfrank's toxicologic emergencies. 7th ed.. New York: McGraw-Hill Medical Pub. Division; 2002;p. 741–757
  23. Delk C, Holstege CP, Brady WJ. Electrocardiographic abnormalities associated with poisoning. Am J Emerg Med. 2007;25:672–687
  24. Shanker UR, Webb J, Kotze A. Sodium bicarbonate to treat massive beta blocker overdose. Emerg Med J. 2003;20:393
  25. Donovan KD, Gerace RV, Dreyer JF. Acebutolol-induced ventricular tachycardia reversed with sodium bicarbonate. J Toxicol Clin Toxicol. 1999;37:481–484
  26. Neuvonen PJ, Elonen E, Vuorenmaa T, et al. Prolonged Q-T interval and severe tachyarrhythmias, common features of sotalol intoxication. Eur J Clin Pharmacol. 1981;20:85–89
  27. Assimes TL, Malcolm I. Torsade de pointes with sotalol overdose treated successfully with lidocaine. Can J Cardiol. 1998;14:753–756
  28. Alderfliegel F, Leeman M, Demaeyer P, et al. Sotalol poisoning associated with asystole. Intensive Care Med. 1993;19:57–58
  29. Montagna M, Groppi A. Fatal sotalol poisoning. Arch Toxicol. 1980;43:221–226
  30. Yalta K, Turgut O, Yilmaz A, et al. Torsades de pointes with a severely prolonged QT interval induced by an initial low dose sotalol intake. Int J Cardiol. 2007;116:e95–e97
  31. Farhangi V, Sansone RA. QTc prolongation due to propranolol overdose. Int J Psychiatry Med. 2003;33:201–202
  32. Love JN, Enlow B, Howell JM, et al. Electrocardiographic changes associated with beta-blocker toxicity. Ann Emerg Med. 2002;40:603–610
  33. Love JN, Howell JM, Litovitz TL, et al. Acute beta blocker overdose: factors associated with the development of cardiovascular morbidity. J Toxicol Clin Toxicol. 2000;38:275–281
  34. Reith DM, Dawson AH, Epid D, et al. Relative toxicity of beta blockers in overdose. J Toxicol Clin Toxicol. 1996;34:273–278
  35. Montgomery AB, Stager MA, Schoene RB. Marked suppression of ventilation while awake following massive ingestion of atenolol. Chest. 1985;88:920–921
  36. Love JN, Elshami J. Cardiovascular depression resulting from atenolol intoxication. Eur J Emerg Med. 2002;9:111–114
  37. Langemeijer JJ, de Wildt DJ, de Groot G, et al. Central origin of respiratory arrest in beta-blocker intoxication in rats. Toxicol Appl Pharmacol. 1987;89:399–407
  38. Fischer W. Anticonvulsant profile and mechanism of action of propranolol and its two enantiomers. Seizure. 2002;11:285–302
  39. Fischer W, Lasek R, Muller M. Anticonvulsant effects of propranolol and their pharmacological modulation. Pol J Pharmacol Pharm. 1985;37:883–896
  40. Amabeoku GJ, Syce JA. Propranolol-induced seizures in mice: the role of noradrenaline. Cell Mol Life Sci. 1997;53:646–651
  41. Wallin CJ, Hulting J. Massive metoprolol poisoning treated with prenalterol. Acta Med Scand. 1983;214:253–255
  42. Das G, Ferris JC. Generalized convulsions in a patient receiving ultrashort-acting beta-blocker infusion. Drug Intell Clin Pharm. 1988;22:484–485
  43. Maebara C, Ohtani H, Sugahara H, et al. Nightmares and panic disorder associated with carvedilol overdose. Ann Pharmacother. 2002;36:1736–1740
  44. Love JN. Beta-blocker toxicity: a clinical diagnosis. Am J Emerg Med. 1994;12:356–357
  45. Frishman W, Jacob H, Eisenberg E, et al. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 8. Self-poisoning with beta-adrenoceptor blocking agents: recognition and management. Am Heart J. 1979;98:798–811
  46. Weinstein RS, Cole S, Knaster HB, et al. Beta blocker overdose with propranolol and with atenolol. Ann Emerg Med. 1985;14:161–163
  47. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blocker use in patients with reversible airway disease. Cochrane Database Syst Rev. 2001;CD002992
  48. Pettei MJ, Levy J, Abramson S. Nonocclusive mesenteric ischemia associated with propranolol overdose: implications regarding splanchnic circulation. J Pediatr Gastroenterol Nutr. 1990;10:544–547
  49. Bird S. Beta adrenerigic antagonists. In:  Shannon M,  Borron S,  Burns M editor. Haddad and Winchester's clinical management of poisoning and drug overdose. 4th ed.. Philadelphia (Pa): Saunders Elsevier; 2007;p. 975–982
  50. Haffner CA, Kendall MJ. Metabolic effects of beta 2-agonists. J Clin Pharm Ther. 1992;17:155–164
  51. Hamad A, Salameh M, Zihlif M, et al. Life-threatening hyperkalemia after intravenous labetolol injection for hypertensive emergency in a hemodialysis patient. Am J Nephrol. 2001;21:241–244
  52. Bell DS. Advantages of a third-generation beta-blocker in patients with diabetes mellitus. Am J Cardiol. 2004;93:B49–B52
  53. Eibs HG, Oberdisse U, Brambach U. Intoxication by beta-blockers in children and adolescents. Monatsschr Kinderheilkd. 1982;130:292–295
  54. Love JN, Sikka N. Are 1-2 tablets dangerous? Beta-blocker exposure in toddlers. J Emerg Med. 2004;26:309–314
  55. Love JN, Howell JM, Klein-Schwartz W, et al. Lack of toxicity from pediatric beta-blocker exposures. Hum Exp Toxicol. 2006;25:341–346
  56. Link MS, Foote CB, Sloan SB, et al. Torsade de pointes and prolonged QT interval from surreptitious use of sotalol: use of drug levels in diagnosis. Chest. 1997;112:556–557
  57. Vale JA, Kulig K. Position paper: gastric lavage. J Toxicol Clin Toxicol. 2004;42:933–943
  58. Soni N, Baines D, Pearson IY. Cardiovascular collapse and propranolol overdose. Med J Aust. 1983;2:629–630
  59. Krenzelok EP. Ipecac syrup-induced emesis…no evidence of benefit. Clin Toxicol (Phila). 2005;43:11–12
  60. Manoguerra AS, Cobaugh DJ. Guideline on the use of ipecac syrup in the out-of-hospital management of ingested poisons. Clin Toxicol (Phila). 2005;43:1–10
  61. Wax PM, Erdman AR, Chyka PA, et al. beta-blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2005;43:131–146
  62. Karkkainen S, Neuvonen PJ. Effect of oral charcoal and urine pH on sotalol pharmacokinetics. Int J Clin Pharmacol Ther Toxicol. 1984;22:441–446
  63. Position paper: whole bowel irrigation. J Toxicol Clin Toxicol. 2004;42:843–854
  64. Kerns W. Management of beta-adrenergic blocker and calcium channel antagonist toxicity. Emerg Med Clin North Am. 2007;25:309–331
  65. Rooney M, Massey KL, Jamali F, et al. Acebutolol overdose treated with hemodialysis and extracorporeal membrane oxygenation. J Clin Pharmacol. 1996;36:760–763
  66. Saitz R, Williams BW, Farber HW. Atenolol-induced cardiovascular collapse treated with hemodialysis. Crit Care Med. 1991;19:116–118
  67. Salhanick SD, Wax PM. Treatment of atenolol overdose in a patient with renal failure using serial hemodialysis and hemoperfusion and associated echocardiographic findings. Vet Hum Toxicol. 2000;42:224–225
  68. Strubelt O. Evaluation of antidotes against the acute cardiovascular toxicity of propranolol. Toxicology. 1984;31:261–270
  69. Langemeijer J, de Wildt D, de Groot G, et al. Calcium interferes with the cardiodepressive effects of beta-blocker overdose in isolated rat hearts. J Toxicol Clin Toxicol. 1986;24:111–133
  70. Love JN, Hanfling D, Howell JM. Hemodynamic effects of calcium chloride in a canine model of acute propranolol intoxication. Ann Emerg Med. 1996;28:1–6
  71. Pertoldi F, D'Orlando L, Mercante WP. Electromechanical dissociation 48 hours after atenolol overdose: usefulness of calcium chloride. Ann Emerg Med. 1998;31:777–781
  72. Glick G, Parmley WW, Wechsler AS, et al. Glucagon. Its enhancement of cardiac performance in the cat and dog and persistence of its inotropic action despite beta-receptor blockade with propranolol. Circ Res. 1968;22:789–799
  73. Kosinski EJ, Malindzak GS. Glucagon and isoproterenol in reversing propranolol toxicity. Arch Intern Med. 1973;132:840–843
  74. Kerns W, Schroeder D, Williams C, et al. Insulin improves survival in a canine model of acute beta-blocker toxicity. Ann Emerg Med. 1997;29:748–757
  75. Love JN, Leasure JA, Mundt DJ, et al. A comparison of amrinone and glucagon therapy for cardiovascular depression associated with propranolol toxicity in a canine model. J Toxicol Clin Toxicol. 1992;30:399–412
  76. Sato S, Tsuji MH, Okubo N, et al. Milrinone versus glucagon: comparative hemodynamic effects in canine propranolol poisoning. J Toxicol Clin Toxicol. 1994;32:277–289
  77. Manchester JH, Parmley WW, Matloff JM, et al. Effects of glucagon on myocardial oxygen consumption and coronary blood flow in man and in dog. Circulation. 1970;41:579–588
  78. Toet AE, Wemer J, Vleeming W, et al. Experimental study of the detrimental effect of dopamine/glucagon combination in d,l-propranolol intoxication. Hum Exp Toxicol. 1996;15:411–421
  79. Parmley WW, Glick G, Sonnenblick EH. Cardiovascular effects of glucagon in man. N Engl J Med. 1968;279:12–17
  80. Zaloga GP, DeLacey W, Holmboe E, et al. Glucagon reversal of hypotension in a case of anaphylactoid shock. Ann Intern Med. 1986;105:65–66
  81. Chernow B, Zaloga GP, Malcolm D, et al. Glucagon's chronotropic action is calcium dependent. J Pharmacol Exp Ther. 1987;241:833–837
  82. Yao LF, MacLeod KM, McNeill JH. Glucagon-induced densensitization: correlation between cyclic AMP levels and contractile force. Eur J Pharmacol. 1982;79:147–150
  83. White CM. A review of potential cardiovascular uses of intravenous glucagon administration. J Clin Pharmacol. 1999;39:442–447
  84. Burda AM, Kapustka CA. Reformulated glucagon diluent phenol-free. J Toxicol Clin Toxicol. 1999;37:127
  85. Masters TN, Glaviano VV. The effects of norepinephrine and propranolol on myocardial subcellular distribution of triglycerides and free fatty acids. J Pharmacol Exp Ther. 1972;182:246–255
  86. Masters TN, Glaviano VV. Effects of dl-propranolol on myocardial free fatty acid and carbohydrate metabolism. J Pharmacol Exp Ther. 1969;167:187–193
  87. Liang C, Doherty JU, Faillace R, et al. Insulin infusion in conscious dogs. Effects on systemic and coronary hemodynamics, regional blood flows, and plasma catecholamines. J Clin Invest. 1982;69:1321–1336
  88. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care?. J Clin Invest. 2004;114:1187–1195
  89. Holger JS, Engebretsen KM, Fritzlar SJ, et al. Insulin versus vasopressin and epinephrine to treat beta-blocker toxicity. Clin Toxicol (Phila). 2007;45:396–401
  90. Kerns W, Ransom M, Tomaszewski C, et al. The effects of extracellular ions on beta-blocker cardiotoxicity. Toxicol Appl Pharmacol. 1996;137:1–7
  91. Van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med. 2003;31:359–366
  92. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359–1367
  93. Weinstein RS. Recognition and management of poisoning with beta-adrenergic blocking agents. Ann Emerg Med. 1984;13:1123–1131
  94. Shore ET, Cepin D, Davidson MJ. Metoprolol overdose. Ann Emerg Med. 1981;10:524–527
  95. Lewis M, Kallenbach J, Germond C, et al. Survival following massive overdose of adrenergic blocking agents (acebutolol and labetalol). Eur Heart J. 1983;4:328–332
  96. Critchley JA, Ungar A. The management of acute poisoning due to beta-adrenoceptor antagonists. Med Toxicol Adverse Drug Exp. 1989;4:32–45
  97. Prichard BN, Battersby LA, Cruickshank JM. Overdosage with beta-adrenergic blocking agents. Adverse Drug React Acute Poisoning Rev. 1984;3:91–111
  98. Whitehurst VE, Vick JA, Alleva FR, et al. Reversal of propranolol blockade of adrenergic receptors and related toxicity with drugs that increase cyclic AMP. Proc Soc Exp Biol Med. 1999;221:382–385
  99. Arstall MA, Hii JT, Lehman RG, et al. Sotalol-induced torsade de pointes: management with magnesium infusion. Postgrad Med J. 1992;68:289–290
  100. Lane AS, Woodward AC, Goldman MR. Massive propranolol overdose poorly responsive to pharmacologic therapy: use of the intra-aortic balloon pump. Ann Emerg Med. 1987;16:1381–1383
  101. McVey FK, Corke CF. Extracorporeal circulation in the management of massive propranolol overdose. Anaesthesia. 1991;46:744–746
  102. Kenyon CJ, Aldinger GE, Joshipura P, et al. Successful resuscitation using external cardiac pacing in beta adrenergic antagonist-induced bradyasystolic arrest. Ann Emerg Med. 1988;17:711–713
  103. Love JN. Beta blocker toxicity after overdose: when do symptoms develop in adults?. J Emerg Med. 1994;12:799–802

PII: S1522-8401(07)00098-5

doi: 10.1016/j.cpem.2007.12.001

Clinical Pediatric Emergency Medicine
Volume 9, Issue 1 , Pages 4-16 , March 2008

Article Tools